| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Odense University Hospital |
| Information provided by: | Odense University Hospital |
| ClinicalTrials.gov Identifier: | NCT00675168 |
Purpose
The prognosis of lung cancer depends much on the stage of the disease at the time of diagnosis. Only 16 % of lung cancer can be offered curative intended surgery. Chest x-ray is the gate-keeper in lung cancer diagnosis, but it has a miss rate of 20-60 %. A false negative chest x-ray often causes prolonged delay in diagnosis - often months.
Recently a "48 hour diagnosis guaranty" has been implemented, which helps accelerate the system delay (delay from referral to diagnosis). But chest x-ray is still the gate-keeper; if the chest x-ray is negative further examination ceases.
PET/CT has a higher sensitivity (96 %), than chest x-ray. In the latter years only little improvement in the survival rate of lung cancer has been made. Screening studies is currently been performed, but it's time for innovative thinking. PET/CT has established its place in the staging of lung cancer. But studies like this may help to place PET/CT in the chain of examination making it more cost-beneficial.
The overall aim of this study is to improve patient course with earlier diagnosis of lung cancer.
| Condition | Intervention | Phase |
|
Lung Cancer |
Radiation: PET/CT (low-dose) |
Phase IV |
| MedlinePlus related topics: | CT Scans Cancer Lung Cancer X-Rays |
| Drug Information available for: | Deoxyglucose |
| Study Type: | Interventional |
| Study Design: | Diagnostic, Non-Randomized, Single Blind (Outcomes Assessor), Historical Control, Single Group Assignment, Efficacy Study |
| Official Title: | PET/CT and Roentgen in Lung Cancer. Evaluation of Patients in General Practice |
| Estimated Enrollment: | 1700 |
| Study Start Date: | May 2008 |
| Estimated Study Completion Date: | June 2012 |
| Estimated Primary Completion Date: | June 2010 (Final data collection date for primary outcome measure) |
 |
Show Detailed Description |
Eligibility
| Ages Eligible for Study: | 60 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: Mie Jung Nielsen, MD | 45-6541-2981 | mie.nielsen@ouh.regionsyddanmark.dk |
| Contact: Poul Flemming Højlund Carlsen, MD, Professor, DMSc | 45-6541-2981 |
| Denmark, Funen | |||||
| Department of Nuclear Medicine | |||||
| Odense, Funen, Denmark, 5000 | |||||
| Odense University Hospital |
More Information
| Responsible Party: | Odense University Hospital, Department of Nuclear Medicine ( Mie Jung Nielsen, MD ) |
| Study ID Numbers: | PROLOG |
| First Received: | May 6, 2008 |
| Last Updated: | May 7, 2008 |
| ClinicalTrials.gov Identifier: | NCT00675168 |
| Health Authority: | Denmark: The Danish National Committee on Biomedical Research Ethics; Denmark: Danish Dataprotection Agency |
|
|
|
|
